Gsk Share Discussion Threads

[redtom1] 19/1/2022 16:40

That does surprise me. Rumours were inaccurate then. But City rumours are often taken with a pinch of salt!

[uppompeii] 19/1/2022 16:37

Not what has just been released redtom1.

[spoole5] 19/1/2022 16:35

That's it then. It will be listed

[panache1] 19/1/2022 16:33

Unilever have announced they're not paying any more !

[redtom1] 19/1/2022 16:22

Contrary to the view of many, the deal is still alive as per my City sources. Expect a final offer around £55bn

[philanderer] 19/1/2022 15:30

Glaxo courts Qatar and Singapore to head off £50bn Unilever swoop

GlaxoSmithKline is courting the sovereign wealth funds of Qatar and Singapore as cornerstone investors in a listing of its £50bn consumer business as it seeks to head off a risky takeover by Unilever.

The FTSE 100 pharmaceuticals titan will formally open discussions with state-owned funds after GSK’s capital markets day next month in a bid to shore up support ahead of a float slated for mid-2022.

Securing the backing of a sovereign wealth fund will allow GSK to offer an exit to investors who do not wish to hold stock in the new company. The Qatar Investment Authority and Singapore’s GIC are among those that will be targeted, it is understood.

[spoole5] 19/1/2022 15:01

Very little to sustain it until results now

[jonjoneil] 19/1/2022 14:53

Is there anything now to stop these drifting back to £16. Q4 results due 9th Feb.
Can anyone detail Hal's successes? I know he made some poor decisions. Collaboration with Merck, I believe, was one.

[alphorn] 19/1/2022 14:31

Does anyone have a quick link to the geographic spread of the business. That could help identify those groups interested.

[spoole5] 19/1/2022 14:22

P&G not interested.

[spoole5] 19/1/2022 14:09

Looking at both prices offer must have been ditched. Will there be another?

[watfordhornet] 19/1/2022 13:15

Has he delivered as expected since he joined?

[geckotheglorious] 19/1/2022 12:40

Spyder

Yes Hal leaving is a disappointment but his replacement is also pretty capable.

Only linked the new article for general interest so thanks for the colour on BOA PT beign for ADRs etc..

[essentialinvestor] 19/1/2022 11:27

Bid was dead on Monday morning, arguably by 8.05 and if not then by midday.

Jope reportedly met with some ii's yesterday and would expect
the message was loud and clear.

Face saving exercise to come now.

[spoole5] 19/1/2022 11:22

Assuming there will be more

[alphorn] 19/1/2022 11:19

Altos is a fascinating move - plenty of blue sky and one to watch.

[pander45] 19/1/2022 11:06

Best to hold from that perspective as every bid will trigger a jump.

[medieval blacksmith] 19/1/2022 10:47

GSK's research chief Hal Barron jumps ship

In a big blow to Britain’s second-biggest drugmaker GSK, its highly regarded chief scientific officer Hal Barron is jumping ship, to lead an anti-ageing Silicon Valley start-up in August.

Barron, who was one of GSK chief executive Emma Walmsley’s key hires in late 2017, will be replaced by Tony Wood as GSK’s CSO on 1 August. Barron will join the biotech Altos Labs, based in the San Francisco bay area, which is reportedly backed by billionaires including Amazon founder Jeff Bezos. The 60-year-old veteran of Genentech and Roche will stay on GSK’s board, however.

Walmsley said:

We are delighted to appoint Tony as our next CSO. He is an outstanding scientist who is highly respected inside and outside GSK. Tony has been a key partner to Hal in delivering our R&D approach, and with his experience and expertise across science, data and new technologies, he is perfectly placed to build on Hal’s outstanding progress and to deliver value from our pipeline. Hal’s appointment to Altos Labs is a unique opportunity for him and we are pleased that GSK will continue to benefit from his expertise at the Board and in support of R&D.

Barron said:

Tony will be an outstanding Chief Scientific Officer for GSK. I have worked closely with him for several years. I know him as a person and scientist of the highest quality. In the last four years we have significantly improved the quality and strength of the pipeline and our overall R&D productivity, delivering 13 major product approvals and more than doubling the number of assets in Phase III/registration to 23. GSK now has a pipeline of 21 vaccines and 42 medicines.

[panache1] 19/1/2022 10:40

And when it does, it's a buy again !

[spoole5] 19/1/2022 10:19

Deal is dead, unless someone else comes knocking this is back sub 16 for the time being

[spyder] 19/1/2022 08:57

—>GtG
The ADRs are for 2 shares, so the BoA $41.55 PT is equivalent to £15.27, so pretty pedestrian, hence neutral rating.
Incidentally, the ADR closing price last night is equivalent to £17.20!
The Credit Suisse PT of £14 is frankly laughable, you wonder why Ian Mackay gives them the time of day.
The news that Hal Barron is leaving is a bit of a blow, but the 1st August date hints at the date for the demerger to be completed?
I can’t help feeling that there should be more to play for here …

[rogerrail] 19/1/2022 08:36

Tax is no concern of the buyer, and if there is a lot of tax to pay that just indicates a huge profit has been realised. No doubt the accountants will find ways to balance the gains against write-downs elsewhere. As I said this is probably just more hype.

[ianood] 19/1/2022 08:25

And the CGT implications to GSK are?

There's a lot more to be considered than just the gross sum.

[rogerrail] 19/1/2022 08:18

On what basis is 60billion justified? The whole of GSK is only valued at 85b even after the recent spike though granted there is some debt to add to that.

Article below from ic suggests 24billion (edit valuation of I guess the 68% share)



Also on the basis of a 4:1 split in the divi and shareholders getting 54.4% of consumer , that would suggest a valuation around the 30billion level.

Personally I don't care for the consumer business especially on a low divi, pharma is where the big growth is. I am afraid that a gift horse could be rejected through overhyped rhetoric, I believe gsk should be looking for 50 billion all in cash and get the deal done.

[garycook] 18/1/2022 22:52

So BofA,PT around £30 ?